Replimune Group, Inc.
General ticker "REPL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $784.3M (TTM average)
Replimune Group, Inc. does not follow the US Stock Market performance with the rate: -12.6%.
Estimated limits based on current volatility of 3.8%: low 9.85$, high 10.63$
Factors to consider:
- Total employees count: 331 (+16.5%) as of 2024
- Top business risk factors: Regulatory and compliance, Operational and conduct risks, Market competition, Supply chain disruptions, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [7.52$, 18.75$]
- 2026-03-31 to 2027-03-31 estimated range: [6.06$, 15.63$]
Financial Metrics affecting the REPL estimates:
- Negative: with PPE of -3.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -22.08 <= 0.33
- Positive: Shareholder equity ratio, % of 75.43 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -4.48 < Investing cash flow per share per price, % of -2.73
- Positive: Interest expense per share per price, % of 0.91 <= 3.41
Short-term REPL quotes
Long-term REPL plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $177.08MM | $234.77MM | $261.63MM |
| Operating Income | $-177.08MM | $-234.77MM | $-261.63MM |
| Non-Operating Income | $3.08MM | $19.39MM | $14.80MM |
| Interest Expense | $1.96MM | $4.50MM | $7.89MM |
| R&D Expense | $129.44MM | $176.88MM | $189.45MM |
| Income(Loss) | $-174.00MM | $-215.39MM | $-246.83MM |
| Taxes | $0.29MM | $0.41MM | $0.47MM |
| Profit(Loss)* | $-174.28MM | $-215.79MM | $-247.30MM |
| Stockholders Equity | $555.29MM | $374.51MM | $415.84MM |
| Assets | $646.59MM | $487.72MM | $551.33MM |
| Operating Cash Flow | $-128.05MM | $-185.47MM | $-192.25MM |
| Capital expenditure | $2.27MM | $5.66MM | $6.69MM |
| Investing Cash Flow | $-142.50MM | $97.20MM | $-23.80MM |
| Financing Cash Flow | $311.30MM | $16.28MM | $252.40MM |
| Earnings Per Share** | $-2.99 | $-3.24 | $-3.07 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.